News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Svelte Medical Systems, Inc. Announces Treatment of First Patient in the DIRECT Drug-Eluting Stent Study


11/8/2011 9:09:43 AM

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand. DIRECT is a First-In-Man, multi-center clinical study designed to assess the feasibility of Svelte’s novel ‘All-In-One’ system, which combines a thin-strut cobalt chromium stent with a fully bio-erodable drug carrier and the well-studied sirolimus (rapamycin) drug, mounted on Svelte’s novel fixed-wire delivery system. The ‘All-In-One’ system is low profile and highly flexible, navigating through the vasculature similar to a traditional guidewire, allowing physicians to ‘direct-stent’ coronary artery lesions and eliminate several steps in their current stenting procedures, thereby reducing procedure time and cost.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES